Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dexcom (DXCM) Non-Current Assets (2016 - 2025)

Dexcom (DXCM) has disclosed Non-Current Assets for 16 consecutive years, with $2.3 billion as the latest value for Q4 2025.

  • On a quarterly basis, Non-Current Assets rose 5.66% to $2.3 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $1.5 billion, a 130.2% increase, with the full-year FY2025 number at $2.3 billion, up 5.66% from a year prior.
  • Non-Current Assets was $2.3 billion for Q4 2025 at Dexcom, up from -$5.2 billion in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $2.3 billion in Q4 2025 to a low of -$5.2 billion in Q3 2025.
  • A 5-year average of -$498.3 million and a median of $1.2 billion in 2021 define the central range for Non-Current Assets.
  • Peak YoY movement for Non-Current Assets: crashed 403.52% in 2022, then soared 155.84% in 2023.
  • Dexcom's Non-Current Assets stood at $1.2 billion in 2021, then soared by 37.95% to $1.7 billion in 2022, then grew by 6.72% to $1.8 billion in 2023, then rose by 18.74% to $2.2 billion in 2024, then increased by 5.66% to $2.3 billion in 2025.
  • Per Business Quant, the three most recent readings for DXCM's Non-Current Assets are $2.3 billion (Q4 2025), -$5.2 billion (Q3 2025), and $2.2 billion (Q1 2025).